Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据;Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2022-09-23 网络 网络

Rhizen新一代PARP1/2抑制剂RP12146完成了剂量递增阶段试验,具有良好的安全性,并已进入实体瘤的剂量扩展阶段试验

总部位于瑞士的私营临床阶段生物制药公司Rhizen Pharmaceuticals AG (Rhizen)今天宣布,于2022年9月9日至13日在巴黎举行的2022年欧洲肿瘤内科学会年会(ESMO 2022)上展示正在进行的Tenalisib治疗局部晚期或转移性乳腺癌的II期试验数据,以及RP12146的剂量递增阶段的结论数据。

 

Tenalisib是一种具有额外SIK3抑制活性的分化型PI3K δ/γ抑制剂。该多中心随机II期研究评估了两种剂量的Tenalisib。目前II期研究已经完成24周的治疗,临床获益率(CBR)达到令人印象深刻的57.5%,且未出现意料之外的安全问题。研究表明口服Tenalisib对大多数具有内脏疾病和多发性转移病灶的难治人群具有疗效。此外,试验中仅一名三阴性乳腺癌(TNBC)患者病情稳定超过6个月,并且正在继续参与研究。

 

RP12146是新一代PARP 1/2抑制剂,旨在克服与第一代PARP抑制剂相关的安全责任问题。该抑制剂的I/Ib期试验的剂量递增试验已经成功完结,正在以二期推荐剂量(RP2D)进行扩展阶段的招募。剂量相关的RP12146暴露显示出强大的靶点结合作用,并且明显没有血液学毒性(即贫血和细胞减少)。目前该研究正针对具有HRR基因突变的卵巢癌、乳腺癌和前列腺癌患者进行400mg BID剂量的扩展阶段试验。

 

Rhizen Pharmaceuticals AG创始人兼首席执行官Swaroop Vakkalanka表示:我们很高兴报告我们资产的临床进展,尤其是Tenalisib在难治性转移性乳腺癌患者群体中显示出持续和有益的疾病控制能力。此外,我们精心设计的新一代PARP1/2抑制剂已经成功展示出与第一代药物不同的安全性,我们正计划在各种实体肿瘤的单药治疗和合理组合给药治疗中迅速开展疗效评估。

 

  1. Tenalisib海报演讲安排:
    224P - II期研究的结果:PI3K delta/gamma和SIK3抑制剂Tenalisib在局部晚期或转移性乳腺癌患者中的疗效和安全性
    演讲编号:224P
    演讲人:Tamta Makharadze(格鲁吉亚第比利斯)
    海报会议:转移性乳腺癌 
    日期:2022年9月10日(周六)
    4号厅:演讲时间:(中欧夏令时间12:00-13:00)

 

  1. RP12146海报演讲安排:
    483P - RP12146(一种PARP1/2抑制剂)在实体瘤中的安全性和抗肿瘤活性的临床前和早期临床评估
    演讲编号:483P
    演讲人:Piotr Tomczak(波兰波兹南)
    海报会议:开发性疗法
    日期:2022年9月12日(周一)
    4号厅:演讲时间:(中欧夏令时间12:00-13:00)

 

关于Rhizen Pharmaceuticals AG

 

Rhizen Pharmaceuticals是一家临床阶段创新生物制药公司,专注于发现和开发新型肿瘤和炎症治疗药物。自2008年成立以来,Rhizen已打造了针对多种癌症和免疫相关细胞通路的多元化专有候选药物产品线。

 

Rhizen总部位于瑞士巴塞尔。如需了解更多信息,请访问https://www.rhizen.com/。

 

前瞻性陈述

 

本新闻稿可能包含与公司及其业务相关的某些前瞻性陈述。尽管公司认为其预期是基于合理的假设,但本新闻稿包含的关于未来事件的历史事实陈述以外的所有陈述均可能发生(i)更改(恕不另行通知)和(ii)超出公司掌控范围的因素。上述陈述可能包含但不限于任何前置、后置或包含下列措辞的陈述:诸如“目标”、“相信”、“期望”、“旨在”、“意图”、“可能”、“预期”、“估计”、“计划”、“项目”、“将要”、“可以有”、“接近”、“应该”、“肯定”、“或可”以及其他具有相似含义的措辞和术语或其否定词。前瞻性陈述涉及某些风险、不确定性和其他因素,或可导致公司的实际结果、财务状况、业绩或成就与此类陈述所明示或暗示的内容存在重大差异。因此,读者不应过分依赖上述陈述,尤其是与任何合同或投资决定无关的陈述。除法律要求外,公司没有义务来更新任何此类前瞻性陈述,或更新实际结果可能与前瞻性陈述中预期结果存在重大差异的原因,即使将来有新信息可用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-07-06 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-06-26 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-03-10 liuhuangbo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2023-02-05 jj000001
  8. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-09-15 zhang92560
  9. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Jul 06 22:48:51 CST 2023, time=2023-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025286, encodeId=f9842025286a8, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon Feb 27 04:48:51 CST 2023, time=2023-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996520, encodeId=7046199652016, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 26 21:48:51 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024955, encodeId=33ae2024955b3, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Mar 10 13:48:51 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Fri Oct 07 07:48:51 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908746, encodeId=00851908e4688, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 01:48:51 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787831, encodeId=58251e87831ea, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Feb 05 12:48:51 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387036, encodeId=aef5138e0367f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406212, encodeId=67b714062125d, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Sep 15 04:48:51 CST 2022, time=2022-09-15, status=1, ipAttribution=)]
    2022-09-15 chg122

相关资讯

传奇生物第二款出海CAR-T LB1901,在美国临床试验终止

临床暂停解除6周之后,7月7日,传奇生物通知美国食品药品监督管理局(FDA),终止其针对CAR-T 新药LB1901的新药临床试验申请(IND)的1期临床试验。

武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果

数据显示,HYQVIA®[免疫球蛋白输注液10%(人类)暨重组人类透明质酸酶]维持治疗组的慢性炎性脱髓鞘性多发性神经根神经病复发率低于安慰剂

新规来了!药物临床试验期间方案变更技术指导原则(试行)

适用于与注册相关的中药、化药、生物制品(含疫苗)相关的临床试验方案变更。

百奥赛图与TRACON共同宣布YH001(CTLA-4单抗)联合恩沃利单抗(PD-L1)一线治疗软组织肉瘤的临床试验申请获得FDA批准

此项临床1/2期试验将评估YH001联合恩沃利单抗在罕见的肺泡软组织肉瘤和软骨肉瘤患者中的安全性和有效性;并评估YH001、恩沃利单抗和阿霉素联合治疗常见的平滑肌肉瘤和去分化脂肪肉瘤的安全性和有效性。

ERS上呈报的CONVERT临床试验数据显示,AeriSeal系统治疗晚期慢性阻塞性肺病/肺气肿患者取得初步成功

呈报数据提示,采用AeriSeal系统闭合侧支空气通道后,侧支通气患者有可能通过Zephyr支气管内瓣膜得到成功治疗

Trials:循证中医推拿治疗与扶他林乳胶剂外用治疗膝骨关节炎的随机、平行对照多中心临床试验

为临床医生提供膝骨关节炎(KOA)患者的补充和替代治疗方法,并评估循证中医推拿治疗KOA与外用双氯芬酸二乙胺乳胶剂(扶他林)的疗效和安全性。

拓展阅读

徐兵河院士:乳腺癌临床研究的进展与未来

在2024南北汇暨第六届中华乳腺肿瘤论坛上,中国医学科学院肿瘤医院徐兵河院士分享了学术报告——《乳腺癌临床研究的进展与未来》,重点分享了其所在团队取得的研究成果。

《新英格兰医学》最新报道,瑞博西尼可降低25%的乳腺癌复发!

为了降低乳腺癌的术后复发风险,研究者开始考虑将一款细胞周期蛋白依赖激酶4/6的抑制剂加入,这类药物主要是用来调控细胞增殖,比较为大家所知的就是瑞博西尼。

论文解读|Yang Liu/Pan Zheng教授团队揭示创新型RNA递送平台在癌症治疗中的前景

这项研究展示了一个新型的递送平台,它使用镁来形成纳米颗粒,实现了有针对性、高效和安全的RNA递送,对乳腺癌的潜在治疗效益也得到了证明。

Lancet Oncol | coopERA Breast Cancer研究:新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌

该研究旨在比较哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌的疗效和安全性,giredestrant较阿那曲唑能更有效地抑制肿瘤增殖且安全可控。

European Radiology:MR在预测乳腺癌新辅助化疗病理完全缓解中的附加价值

MRI是NAC治疗前分期和肿瘤反应监测的首选方法,并可以使用形态学和功能学参数 (如弥散加权成像)来提高NAC治疗后肿瘤反应的预测。

【专家访谈】靶向药物拓展了HR+/HER2-转移性乳腺癌领域的治疗

在演讲中,Stringer-Reasor重点介绍了针对HR+/HER2-转移性乳腺癌患者的新型疗法和新兴疗法,解释了目前针对CDK4/6抑制剂一线治疗取得进展的患者能否继续使用CDK4/6抑制剂治疗。

FDA指南:数据监测委员会在临床试验中的使用

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-02-13

阿达木单抗注射液生物类似药临床试验指导原则

国家药品监督管理局药品审评中心(CDE) · 2020-08-03

临床试验受试者补偿兑付平台实践专家共识

上海市精神卫生中心 · 2023-12-25

FDA指南:在FDA监管的医疗产品的临床试验和临床研究中收集种族和民族数据

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-01-29

临床试验纸质源文件受控管理专家共识

复旦大学附属华山医院 · 2023-12-15